Advanced Diffusion MRI to Differentiate Tumor Recurrence From Pseudoprogression in Patients With Glioblastoma and Brain Metastases

Advanced Diffusion MRI to Differentiate Tumor Recurrence From Pseudoprogression in Patients With Glioblastoma and Brain Metastases- AiD GLIO Pilot Trial

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05911230

Acronym

AiD-GLIO

Enrollment

Registered

2023-06-20

Start date

2022-11-24

Completion date

2025-11-30

Last updated

2025-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma (GBM)

Keywords

Advanced Diffusion Weighted Magnetic Resonance Imaging (ADW-MRI), Tumor Progress (TP), Pseudo- Progression (PsP)

Brief summary

This pilot study investigates whether advanced diffusion-weighted MRI (ADW-MRI) can differentiate between true tumor progression (TP) and a pseudoprogression (PsP) in patients with glioblastoma (GBM) or brain metastases.

Detailed description

Advanced diffusion-weighted MRI (ADW-MRI) offer the opportunity of higher sensitivity towards subtle tissue changes associated with increased specificity relating to damage of different tissue components of the central nervous system (CNS). Within the framework of this study, conventional follow up MRI will be complemented by ADW-MRI in case of suspected tumor recurrence and possible surgical resection of the suspicious tissue. In the case of surgical resection, the histopathological findings will be correlated to the findings of the ADW-MRI. In the depicted pilot phase, the feasibility of the described protocol will be examined and the data concerning correlations between standard histopathologic and genetic workup of the resected tissue and the results concerning tissue features from ADW-MRI will be analyzed.

Interventions

DIAGNOSTIC_TESTAdvanced diffusion-weighted MRI (ADW-MRI)

An advanced diffusion weighted MRI-sequence will be performed in addition to the routine MRI-diagnostics. This will require the patient to be scanned for additional 30 minutes in a separate MRI-scanner. This technique offers the opportunity of higher sensitivity towards subtle tissue changes associated with increased specificity relating to damage of different tissue components of the CNS. In the case of surgical resection, the histopathological findings will be correlated to the findings of the ADW-MRI.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Intervention model description

one-arm, monocentric pilot trial

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with histopathologically proven glioblastoma or brain metastasis and suspected tumor progress on standard MRI after first line therapy and who are candidates for elective surgical resection. * Able to give informed consent

Exclusion criteria

* Contraindications to MRI (e.g. claustrophobia, pacemaker or other implants without MRI-approval, pregnancy) * Patients in a life-threatening condition * Patients in need of emergent surgery * Histopathological analyses of insufficient quality * Unable to give informed consent * Age \<18 Years

Design outcomes

Primary

Measure	Time frame	Description
Correlation of ADW-MRI-findings to histopathological findings	one time assessment at baseline	Correlations between standard histopathologic workup of the resected tissue and the results concerning tissue features from ADW-MRI are analyzed (descriptive analysis))

Countries

Switzerland

Contacts

Primary ContactDominik Cordier, PD Dr. med.

dominik.cordier@usb.ch+41 61 26 56 42

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026